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Background
Due to its positive benefit-risk-ratio, methotrexate
(MTX) is a first-line therapy in the treatment of rheu-
matoid arthritis (RA). Although MTX is very effective,
the large interpatient variability in drug response is a
major drawback in clinical practice. Erythrocyte metho-
trexate polyglutamates (MTXPG1–7) — intracellular
storage products of methotrexate — are supposed to
correlate with clinical efficacy. In particular, long-chain
polyglutamates (MTXPG4–5 )a r es t r o n g l yr e t a i n e di n
the cells and are therefore discussed to be potential
markers for clinical response in rheumatoid arthritis.
We hypothesized that concentrations of methotrexate
polyglutamates could correlate with clinical response
parameters in rheumatoid arthritis.
Methods
A randomized, double-blinded controlled clinical trial
including nineteen patients was performed according to
GCP (Good Clinical Practice) guidelines and ethical
principles that have their origin in the Declaration of
Helsinki. Patients received a dose of 25 mg methotrexate
per week administered orally. Laboratory testing and
pharmacokinetics were performed at week 1, week 5,
week 10 and at the end of study in week 16. The pri-
mary outcome parameter for clinical evaluation was
DAS-28 (Disease Activity Score in 28 joints). DAS-28
calculation incorporates clinical parameters (ESR, swol-
len and tender joints) as well as subjective parameters
(VAS pain). For measurement of methotrexate polyglu-
tamates in erythrocytes, we used an HPLC (High Pres-
sure Liquid Chromatography) method with post-column
photooxidation followed by fluorimetric detection.
Results
Correlation of pharmacokinetics and clinical parameters
using Spearman’s correlation coefficient showed a statis-
tically significant positive correlation of Cmax values of
MTXPG2 and improvement in DAS-28 (+0.518, p =
0.023) at week 5. This correlation could indicate that
erythrocyte concentrations of MTXPG2 are relevant for
clinical response and potentially for drug monitoring.
Up to now, only the accumulation of long-chain poly-
glutamates was linked to a good MTX response.
Conclusions
In particular, MTXPG2 seems to be an indicator for
clinical response and may serve as a marker for drug
monitoring. These seminal data should stipulate further
trials to define the potential role of measuring erythro-
cyte concentrations of MTX for clinical prediction of
MTX response.
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